2358-PUB: Efficacy and Safety of Tofogliflozin on 24-hr Glucose Profile Based on Continuous Glucose Monitoring—Crossover Study of Sodium-Glucose Cotransporter 2 Inhibitor
Abstract:Background: Tofogliflozin (TOFO) has the highest selectivity to sodium-glucose co-transporter 2 (SGLT2) relative to SGLT1 (2900 times) and does not promote urinary glucose excretion at hypoglycemia compared with phlorhizin and does not enhance further lowering of glucose. To compare the impact of TOFO and ipragliflozin (IPR) on hypoglycemia in patients with T2DM, treated with sulfonylureas.
Methods: 30 patients were allocated to either 20 mg TOFO or 50 mg IPR and wore a continuous glucose monito… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.